Navigation Links
Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria

The research, done in collaboration with the Centro de Investigación Médica Aplicada (CIMA) at the University of Navarra, Pamplona, Spain, is being presented at Porphyrins and Porphyrias Congress, Rotterdam, the Netherlands.

AMSTERDAM, the Netherlands, May 1st 2007 - Amsterdam Molecular Therapeutics BV (AMT), a leader in the field of human gene therapy, will today present preclinical data on its AMT-020 gene therapy to treat acute intermittent porphyria (AIP) at the Porphyrins and Porphyrias Congress, Rotterdam.

The data suggest that AMT-020 has the potential to protect patients suffering from recurrent porphyria attacks and/or neuropathy.

AMT-020 is comprised of an Adeno-Associated Virus (AAV) vector delivering the gene for porphobilinogen deaminase (PBGD). The aim of this study, which was performed by Dr's Fontanellas, González-Aseguinolaza and Prieto at CIMA, was to investigate the potential of AMT-020 to protect against acute attack induced by phenobarbital (Pb) in a mouse model of AIP. The model reproduces key features of AIP attack after Pb induction, including increased urinary excretion of haem precursors and decreased motor function.

PBGD-deficient female and male mice were intravenously injected with 1x1011 gc/mouse of AMT-020. Control animals received the same AAV vector but carried the luciferase reporter gene.

One month after injection, both groups were treated with an increasing dose of Pb for 4 days to induce a porphyria attack. The results showed that porphyric mice that received AMT-020 had almost normal haem precursors in the urine and normal motor function, indicating that the treatment completely prevented the occurrence of porphyric attacks.

"These results are very encouraging, and show the potential of AMT-020 to treat AIP," said Sander van Deventer, CSO at AMT, who presented the data. "The next stage in the development of the product will be to confirm the ability of our liver-directed vector technology to induce long-term therapeutic protein expression in non-human primates."

-ENDS-

About AMT

Amsterdam Molecular Therapeutics BV (AMT) is a gene therapy company founded by scientists of the University of Amsterdam Medical Center (AMC) in 1998. AMT focuses on the development of gene-based therapies for orphan metabolic and ocular diseases. AMT's long-term gene expression technology is based on specific delivery of therapeutic genes into target organs or tissues. Production of AAV-based gene therapy vectors has been optimized and AMT has developed and validated a unique, stable and scalable GMP production platform. Its lead product, AMT-011, is in phase II for the first indication: treatment of lipoprotein lipase deficiency type I.

The company's Management, Supervisory and Scientific Advisory Board bring together an extensive know-how from both gene science as well as the biotech and pharmaceutical worlds. For further information, go to www.amtbv.com <http://www.amtbv.com/> .

About Acute Intermittent Porphyria

Acute intermittent porphyria is a life threatening inherited disease characterised by a partial deficiency of hepatic porphobilinogen deaminase (PBGD). Clinical symptoms include attacks of acute abdominal pain, muscular weakness and a complex array of neurovisceral and psychiatric symptoms. There is also an increased risk of primary liver cancer and renal failure. The attacks are normally triggered when the haem synthesis is induced by infections, stress, alcohol, hormones, or specific drugs. The prevalence of symptomatic disease is 1-2 per 20,000 individuals, however, in some regions of Sweden the prevalence of the disease can be as high as 60-100 cases per 100,000 population. Women are more commonly affected than men.

About the Cent ro de Investigación Médica Aplicada at the University of Navarra

CIMA is a biomedical research project which aims to improve clinical practice. It was started at the University of Navarra in order to give an organized and systematic response to the need to fight against severe diseases that currently cannot be cured.

About the Porphyrins and Porphyrias Congress 2007

The Porphyrins & Porphyrias meetings are biennial events organised with the aim of providing an environment for active participation of both experienced and new researchers in the field. This years event is held in Rotterdam, The Netherlands between April 29th and May 3rd.

There will be presentations and discussions on all haem synthesis enzymes, including structure and function, molecular/genetic aspects and clinical syndromes. Haem degradation (including haem oxygenase, bilirubinaemias etc.) and iron related topics, and general porphyria. Diagnostics/therapies/clinical issues, including drug porphyrinogenicity will also be covered.

For further information, please contact:

AMT:

Prof. Sander Van Deventer, CSO

Phone: +31 20 566 7394

Email: s.vandeventer@amtbv.com

Northbank Communications:

Adam Michael, Account Director

Phone: +44 20 7268 3233

Email: amt@northbankcommunications.com

Best regards

Holly Griffiths Account Executive --------------------------------------------- Direct line: +44 (0)20 7268 3241 Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102 www.northbankcommunications.com <http://www.northbankcommunications.com/>

Northbank Communications Ltd 85 Tottenham Court Road, London, W1T 4TQ, UK


'"/>




Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
4. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
5. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
9. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
10. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
11. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... MINNEAPOLIS , Feb. 23, 2017  Cogentix Medical, ... manufactures and markets innovative proprietary products for the urology ... and fiscal year ended December 31, 2016 before the ... The Company will host a conference call and ... on Thursday, March 9, 2017 at 11:00 a.m. Eastern ...
(Date:2/23/2017)... 23, 2017 Nevro Corp. (NYSE: NVRO), a global ... the treatment of chronic pain, today reported financial results for ... 2016 Accomplishment & Highlights: ... an increase of 228% as reported, over the prior year ... increase of 612% over the prior year ...
(Date:2/23/2017)... -- Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden ... Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... An in-depth ... at the University of Pittsburgh points to eight genes that may explain why susceptibility ... according to the results of a study published today in the journal npj Schizophrenia. ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care ... a top priority because it’s not if you will be attacked, but when.” However, ... it comes to digital health care. , Improvements in auditing and monitoring have taken ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An ... true account of his paramedic experiences. Schanssema describes the tragedies he saw, as well ... to overcome them. , Schanssema, initially unsure of the career path he wanted to ...
(Date:2/24/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... Yisrayl makes an astounding statement when he says that the entire Bible was ... details the current times so plainly that anyone should be able to see the ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The Radiology ... excellence in radiology marketing programs at the annual Building Better Radiology Marketing Programs ... Fort Worth Hotel in Fort Worth, Texas. Nine awards are given out in five ...
Breaking Medicine News(10 mins):